The Life Sciences Industrial Strategy, supported by Government and led by Sir John Bell, has been launched today in Birmingham.
The ABPI has welcomed the launch of the Strategy (available online), that has been developed in consultation
with the Life Sciences Industrial Strategy Board. The ABPI and ABPI member companies were active members of the Board.
Alongside creating a new Health Advanced Research Programme (HARP), the Strategy seeks to address a series of challenges under five key themes:
Commenting on the launch, ABPI CEO Mike Thompson said:
"Today’s Life Sciences Industrial Strategy is an impressive document which captures the importance of our sector to a successful post-Brexit Britain. Sir John Bell is to be congratulated in pulling together a complex and diverse sector and showing the benefits to the UK of getting us all to align.
We want the UK to be one of the best places in the world for discovering, developing and adopting new medicines and this Strategy provides the focus for all life science partners to work together to deliver exciting medical innovations for patients.
The NHS is rightly at the heart of the strategy: If it can build on its unique capability to use health data in research and development and address the UK’s long-standing challenge of adopting new treatments, it will create a virtuous circle for all and deliver massive health and economic benefits to the UK.
We look forward to working with Government and other partners to implement these recommendations – including through a sector deal with the bio-pharmaceutical industry and a voluntary agreement on UK medicines policy between industry and the Department of Health (see PPRS). These measures will provide confidence for global companies to invest in the UK during and beyond Brexit."
Laern more about ABPI's work on Industrial Strategy.
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone (24hrs): +44 (0) 20 7747 7147
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.